Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study aimed to compare the effect of continuing and discontinuing medications on quality of life of patients with attention-deficit/hyperactivity disorder (ADHD). DATA SOURCES: PubMed, Cochrane Library, and Embase databases were searched using generic terms for ADHD, discontinuing, continuing, pharmacotherapy, and randomized controlled trials without date or language restrictions. STUDY SELECTION: Of the 3,672 screened studies, 9 met the predefined inclusion criteria on patients with ADHD; 5 of these 9 studies reporting on 1,463 patients (children and adolescents, n = 894; adults, n = 569) measured quality of life and were included in this meta-analysis. Only randomized, double-blind, placebo-controlled withdrawal trials of ADHD medications were included. DATA EXTRACTION: Data were independently extracted according to the Cochrane Handbook for Systematic Reviews of Interventions. Analyses were based on random-effects models. RESULTS: Compared with continuing medications, discontinuing them significantly worsened quality of life score in patients with ADHD (standardized mean difference [SMD] = 0.19; 95% CI, 0.08 to 0.30]). Moreover, discontinuing medications worsened this score in children and adolescents with ADHD (SMD = 0.21; 95% CI, 0.06 to 0.36) but not in adults with ADHD (SMD = 0.02; 95% CI, -0.46 to 0.50). CONCLUSIONS: Discontinuing medications was associated with a small but statistically significant decrease in quality of life among children and adolescents with ADHD but not in adults with ADHD. Quality of life can be applied in pharmacologic interventions regarding continuing and discontinuing medication because this concept is related to individuals' appraisal of their situation. Quality of life is an important factor for planning individualized ADHD medication treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A meta-analysis of nine RCTs comprising 1,463 patients found that discontinuing medications led to a worsening in quality of life for children and adolescents but not adults.”
From The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder (2021) · cites this paper as Tsujii et al., 2020
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
The Prevalence of DSM-IV Attention-Deficit/Hyperactivity Disorder: A Meta-Analytic Review
Willcutt, E. G. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0135-8 · Cited by 2,160 · cited 4×
“Full-text articles excluded based on the following reasons (21): • No relevant outcomes (15) • Data was already used (3) • Using modafinil (2) • Other reason (1) Figure 1.”
BackgroundMethodInfluentialPrevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis
Thomas, R., Sanders, S., Doust, J., Beller, E., & Glasziou, P. (2015) · Pediatrics · doi:10.1542/peds.2014-3482 · Cited by 1,976
Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis
Simon, V., Czobor, P., Bálint, S., Mészáros, Á., & Bitter, I. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048827 · Cited by 1,601 · cited 2×
“We used the following search terms: (1) participant terms, eg, ADHD; (2) ADHD medication terms, eg, methylphenidate; (3) intervention terms, eg, withdr*, discontinue*, stop*, and withhold*; (4) comparison terms, eg, continu* and maintenance*; and (5) study design terms, eg, randomized, double-blind, and placebo.”
BackgroundKooij, S. J., Bejerot, S., Blackwell, A., Caci, H., Casas-Brugué, M., Carpentier, P. J., Edvinsson, D., Fayyad, J., Foeken, K., Fitzgerald, M., et al. (2010) · BMC Psychiatry · doi:10.1186/1471-244x-10-67 · Cited by 928 · cited 2×
“We used the following search terms: (1) participant terms, eg, ADHD; (2) ADHD medication terms, eg, methylphenidate; (3) intervention terms, eg, withdr*, discontinue*, stop*, and withhold*; (4) comparison terms, eg, continu* and maintenance*; and (5) study design terms, eg, randomized, double-blind, and placebo.”
BackgroundWehmeier, P. M., Schacht, A., & Barkley, R. A. (2010) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2009.09.009 · Cited by 628
The quality of life of children with attention deficit/hyperactivity disorder: a systematic review
Danckaerts, M., Sonuga-Barke, E. J. S., Banaschewski, T., Buitelaar, J., Döpfner, M., Hollis, C., Santosh, P., Rothenberger, A., Sergeant, J., Steinhausen, H.-C., et al. (2010) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-009-0046-3 · Cited by 516
Attention Deficit Disorder with Hyperactivity
Field, D. S. (1991) · Cited by 44
Banaschewski, T., Johnson, M., Lecendreux, M., Zuddas, A., Adeyi, B., Hodgkins, P., Squires, L. A., & Coghill, D. R. (2014) · CNS Drugs · doi:10.1007/s40263-014-0193-z · Cited by 41
(2021) · doi:10.31003/uspnf_m1417_05_01 · Cited by 1
Research works printed but not linked: 40
- [6]Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36(2):159-165. PubMed CrossRef
- [8]Dalsgaard S, טstergaard SD, Leckman JF, et al. Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet. 2015;385(9983):2190-2196. PubMed CrossRef
- [9]Faraone SV, Asherson P, Banaschewski T, et al. Attention-deficit/hyperactivity disorder. Nat Rev Dis Primers. 2015;1(1):15020. PubMed CrossRef
- [10]Able SL, Johnston JA, Adler LA, et al. Functional and psychosocial impairment in adults with undiagnosed ADHD. Psychol Med. 2007;37(1):97-107. PubMed CrossRef
- [13]Epstein JN, Weiss MD. Assessing treatment outcomes in attention-deficit/hyperactivity disorder: a narrative review. Prim Care Companion CNS Disord. 2012;14(6):11r01336. PubMed
- [14]Coghill DR, Banaschewski T, Soutullo C, et al. Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry. 2017;26(11):1283-1307. PubMed CrossRef
- [15]Kooij JJS, Bijlenga D, Salerno L, et al. Updated European Consensus Statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56(1):14-34. PubMed CrossRef
- [16]Bolea-Alama×±ac B, Nutt DJ, Adamou M, et al; British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2014;28(3):179-203. PubMed CrossRef
- [17]Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921. PubMed CrossRef
- [18]Wolraich M, Brown L, Brown RT, et al; Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007-1022. PubMed CrossRef
- [19]Joseph A, Ayyagari R, Xie M, et al. Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison. Eur Child Adolesc Psychiatry. 2017;26(8):875-897. PubMed CrossRef
- [20]Padilha SCOS, Virtuoso S, Tonin FS, et al. Efficacy and safety of drugs for attention deficit hyperactivity disorder in children and adolescents: a network meta-analysis. Eur Child Adolesc Psychiatry. 2018;27(10):1335-1345. PubMed CrossRef
- [21]Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. PubMed CrossRef
- [22]Yoshida M, Obara T, Kikuchi S, et al. Drug prescriptions for children with ADHD in Japan: a study based on health insurance claims data between 2005 and 2015. J Atten Disord. 2020;24(2):175-191. PubMed CrossRef
- [23]Hales CM, Kit BK, Gu Q, et al. Trends in prescription medication use among children and adolescents—United States, 1999-2014. JAMA. 2018;319(19):2009-2020. PubMed CrossRef
- [24]Renoux C, Shin JY, Dell’ Aniello S, et al. Prescribing trends of attention-deficit hyperactivity disorder (ADHD) medications in UK primary care, 1995-2015. Br J Clin Pharmacol. 2016;82(3):858-868. PubMed CrossRef
- [25]McCarthy S, Asherson P, Coghill D, et al. Attention-deficit hyperactivity disorder: treatment discontinuation in adolescents and young adults. Br J Psychiatry. 2009;194(3):273-277. PubMed CrossRef
- [26]Wehmeier PM, Schacht A, Dittmann RW, et al. Effect of atomoxetine on quality of life and family burden: results from a randomized, placebo-controlled, double-blind study in children and adolescents with ADHD and comorbid oppositional defiant or conduct disorder. Qual Life Res. 2011;20(5):691-702. PubMed CrossRef
- [27]Ingram S, Hechtman L, Morgenstern G. Outcome issues in ADHD: adolescent and adult long-term outcome. Ment Retard Dev Disabil Res Rev. 1999;5(3):243-250. CrossRef
- [28]MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics. 2004;113(4):762-769. PubMed CrossRef
- [29]MTA Cooperative Group. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004;113(4):754-761. PubMed CrossRef
- [30]van de Loo-Neus GH, Rommelse N, Buitelaar JK. To stop or not to stop? how long should medication treatment of attention-deficit hyperactivity disorder be extended? Eur Neuropsychopharmacol. 2011;21(8):584-599. PubMed CrossRef
- [31]Buitelaar J, Asherson P, Soutullo C, et al. Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2015;25(10):1611-1621. PubMed CrossRef
- [32]Coghill D, Danckaerts M, Sonuga-Barke E, et al; ADHD European Guidelines Group. Practitioner review: quality of life in child mental health—conceptual challenges and practical choices. J Child Psychol Psychiatry. 2009;50(5):544-561. PubMed CrossRef
- [33]WHOQOL. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403-1409. PubMed CrossRef
- [34]Ahnemark E, Di Schiena M, Fredman AC, et al. Health-related quality of life and burden of illness in adults with newly diagnosed attention-deficit/hyperactivity disorder in Sweden. BMC Psychiatry. 2018;18(1):223. PubMed CrossRef
- [35]Wong ICK, Banaschewski T, Buitelaar J, et al; European ADHD Guidelines Group. Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorder-outcome measures beyond symptom control and clinical trials. Lancet Psychiatry. 2019;6(6):528-537. PubMed CrossRef
- [36]Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. PubMed CrossRef
- [39]Buitelaar JK, Michelson D, Danckaerts M, et al. A randomized, double-blind study of continuation treatment for attention-deficit/hyperactivity disorder after 1 year. Biol Psychiatry. 2007;61(5):694-699. PubMed CrossRef
- [40]Coghill DR, Banaschewski T, Lecendreux M, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014;53(6):647-657.e1. PubMed CrossRef
- [41]Michelson D, Buitelaar JK, Danckaerts M, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43(7):896-904. PubMed CrossRef
- [42]Newcorn JH, Harpin V, Huss M, et al. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study. J Child Psychol Psychiatry. 2016;57(6):717-728. PubMed CrossRef
- [43]Biederman J, Mick E, Surman C, et al. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2010;30(5):549-553. PubMed CrossRef
- [44]Brams M, Weisler R, Findling RL, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73(7):977-983. PubMed CrossRef
- [45]Buitelaar JK, Trott GE, Hofecker M, et al. Long-term efficacy and safety outcomes with OROS-MPH in adults with ADHD. Int J Neuropsychopharmacol. 2012;15(1):1-13. PubMed CrossRef
- [47]Schwartz CE, Rapkin BD. Reconsidering the psychometrics of quality of life assessment in light of response shift and appraisal. Health Qual Life Outcomes. 2004;2(1):16. PubMed CrossRef
- [49]Osland S, Hirsch L, Pringsheim T. Smoking, alcohol and drug use in youth and adults with attention-deficit hyperactivity disorder. BJPsych Open. 2017;3(3):141-146. PubMed CrossRef
- [50]McCabe SE, Dickinson K, West BT, et al. Age of onset, duration, and type of medication therapy for attention-deficit/hyperactivity disorder and substance use during adolescence: a multi-cohort national study. J Am Acad Child Adolesc Psychiatry. 2016;55(6):479-486. PubMed CrossRef
- [51]Fredriksen M, Halm׸y A, Faraone SV, et al. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013;23(6):508-527. PubMed CrossRef
- Privacy Policy Terms of Use Physicians Postgraduate Press, Inc. JCP ISSN: Online 1555-2101, Print 0160-6689 PCC ISSN: Online 2155-7780, Print 2155-7772 MedFair.com US Patent No. 684794 © Copyright 2026 | Physicians Postgraduate Press, Inc. | LifeLong Learning For Clinicians Sitemap
Cited by
Faraone, S. V., Banaschewski, T., Coghill, D., Zheng, Y., Biederman, J., Bellgrove, M. A., Newcorn, J. H., Gignac, M., Al Saud, N. M., Manor, I., et al. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.022 · Cited by 1,545
“(Tsujii et al., 2020) 160 A Swedish cohort study of over 25,000 ADHD patients found a one-third reduction in criminality among men receiving ADHD medication, and a 40 % reduction for women (Lichtenstein et al., 2012).”
Attention-deficit/hyperactivity disorder
Faraone, S. V., Bellgrove, M. A., Brikell, I., Cortese, S., Hartman, C. A., Hollis, C., Newcorn, J. H., Philipsen, A., Polanczyk, G. V., Rubia, K., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00495-0 · Cited by 355
“Moreover, one RCT demonstrated stable and long-term QoL benefits following multimodal treatment with methylphenidate combined with CBT group treatment or supportive counselling 273 , and a meta-analysis found that discontinuing medication reduce the QoL of youths with ADHD 274 .”
Pharmacologic Treatment of Attention Deficit–Hyperactivity Disorder
Cortese, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1917069 · Cited by 342
Ostinelli, E. G., Schulze, M., Zangani, C., Farhat, L. C., Tomlinson, A., Giovane, C. D., Chamberlain, S. R., Philipsen, A., Young, S., Cowen, P. J., et al. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00360-2 · Cited by 108
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
“Risk factors for relapse following discontinuation: Re-emergence of ADHD symptoms is independent of age and sex, although adults may be at less risk compared to minors after stimulant discontinuation [139, 144].”
Background
Metadata
- Authors
- Tsujii, N., Okada, T., Usami, M., Kuwabara, H., Fujita, J., Negoro, H., Kawamura, M., Iida, J., & Saito, T.
- Affiliations
- Kindai University (JP)
- Nagoya University (JP)
- Kohnodai Hospital, National Center for Global Health and Medicine (JP)
- Yokohama City University Hospital (JP)
- Nara University of Education (JP)
- Hokkaido University (JP)
- Nara Medical University (JP)
- Corresponding author
- Okada, Takashi
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2020-03-24
- Volume
- 81
- Issue
- 3
- ISSN
- 0160-6689 (ISSN-L)
- 1555-2101
- OpenAlex
- W3013248890
- Cited by
- 31
- References
- 6
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 8 · 2021: 2 · 2020: 2
- FWCI
- 0.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Hokkaido University
- Japan Society for the Promotion of Science (19K08044, 17K10339, 16K10248)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- attention deficit hyperactivity disorder, quality of life, symptom remission, drug withdrawal, children and adolescents, adult ADHD, pharmacotherapy
- MeSH terms
- Adolescent, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Humans, Quality of Life, Remission Induction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. https://app.cochat.ai/papers/10.4088/jcp.19r13015
- The paper
- Tsujii, N., Okada, T., Usami, M., Kuwabara, H., Fujita, J., Negoro, H., Kawamura, M., Iida, J., & Saito, T. (2020). Effect of Continuing and Discontinuing Medications on Quality of Life After Symptomatic Remission in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.19r13015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.